<DOC>
	<DOC>NCT00290030</DOC>
	<brief_summary>To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.</brief_summary>
	<brief_title>ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH</brief_title>
	<detailed_description>Double-blind, placebo controlled, randomized Multicenter, Phase III study comparing 2 parallel groups (alfuzosin 10mg OD or placebo) in patients with a first episode of acute urinary retention related to BPH.The acute episode is managed with catheterization and with study drug treatment for 2 to 3 days, followed by an active voiding trial to assess the patients' ability to void after catheter removal. Those patients who successfully void will continue their randomized treatment for a total treatment duration of 6 months. For all patients who are prematurely withdrawn during the study, a post-study (clinic or phone) visit will be performed for collection of health care consumption data.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Urinary Retention</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Male aged over 50 years Having given his written consent Presenting with a first episode of painful acute urinary retention related to BPH With a catheterized urine volume between mL and mL at the time of retention Associated urological diseases / troubles (e.g. infection or surgery of prostate, urinary retention f neurogenic origin Iatrogenic causes of urinary retention</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>acute urinary retention</keyword>
	<keyword>International Prostate Symptom Score (IPSS)</keyword>
</DOC>